Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Non-myeloablative allogeneic stem cell transplantation].

Jakob Dalgaard1, Yngvar Fløisand, Margurethe Stenersen

  • 1Seksjon for blodsykdommer, Medisinsk avdeling, Rikshospitalet-Radiumhospitalet, 0027 Oslo. jakob.dalgaard@sb-hf.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|March 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.

International journal of hematology·2025
Same author

[A man in his 50s with acute renal failure, anemia, and thrombocytopenia].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2025
Same author

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.

Blood advances·2024
Same author

Automated cell type annotation and exploration of single-cell signaling dynamics using mass cytometry.

iScience·2024
Same author

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.

British journal of haematology·2024
Same author

Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.

Nature medicine·2024

Non-myeloablative allogeneic stem cell transplantation (SCT) is a feasible treatment for hematological malignancies with acceptable toxicity. Graft-versus-host disease remains a significant challenge requiring further investigation.

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Oncology

Context:

  • Allogeneic stem cell transplantation (SCT) offers curative potential for hematological malignancies.
  • Conventional SCT regimens involve high-dose chemoradiotherapy, leading to significant toxicity and limiting patient eligibility.
  • Non-myeloablative allogeneic SCT provides a less toxic alternative, expanding treatment options to older patients and those with comorbidities.

Purpose:

  • To evaluate the feasibility and toxicity of non-myeloablative allogeneic SCT in patients with hematological malignancies.
  • To assess outcomes including graft-versus-host disease (GVHD) and survival rates.

Summary:

  • A study involving 21 patients with hematological malignancies treated with non-myeloablative allogeneic SCT demonstrated its feasibility.

Related Experiment Videos

  • The procedure exhibited relatively low toxicity, with stable donor chimerism achieved in most patients.
  • Graft-versus-host disease (acute and chronic) was observed in 11 patients each, representing a substantial challenge.

    • Impact:

    • Non-myeloablative allogeneic SCT is a viable treatment option with manageable toxicity for select patients.
    • Graft-versus-host disease remains a significant concern that necessitates further research and management strategies.
    • Prospective studies are crucial to define the definitive role of non-myeloablative allogeneic SCT in clinical practice.